XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.23.2

Commitments and Contingencies - Additional Information (Details) - USD ($) |  | 6 Months Ended |
--- | --- | --- | ---
May 07, 2019 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022
Commitments And Contingencies [Line Items] |  |  |  |
Common stock fair value |  | $ 5,000 |  | $ 3,000
Common stock, shares issued |  | 56,639,085 |  | 41,723,308
Expenses incurred related to purchase commitments |  | $ 0 | $ 0 |
Minimum |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |
Purchase obligation in the first 24-month period |  | $ 3,800,000 |  |
Takeda License | Takeda |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |
License agreement description |  | The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents. |  |
Agreement expiration term from date of first commercial sale | 15 years |  |  |
Cash consideration paid for license | $ 25,000,000 |  |  |
Common stock fair value | $ 5,900,000 |  |  |
Common stock, shares issued | 1,084,000 |  |  |
Warrants exercise price | $ 0.00004613 |  |  |
Initial fair value of warrants | $ 47,900,000 |  |  |
Additional warrant issued | 0 |  |  |
Maximum amount payable in sales milestones upon achievement of specified levels of product sales | $ 250,000,000 |  |  |
Warrants expiration date | May 07, 2029 |  |  |
Takeda License | Takeda | Common Stock |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |
Warrants issued to purchase shares | 7,588,000 |  |  |

X
- Definition Additional warrant issued. + References No definition available. + Details
Name: | phat_AdditionalWarrantIssued
Namespace Prefix: | phat_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement expiration term from date of first commercial sale. + References No definition available. + Details
Name: | phat_AgreementExpirationTermFromDateOfFirstCommercialSale
Namespace Prefix: | phat_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | phat_CommitmentsAndContingenciesLineItems
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement description. + References No definition available. + Details
Name: | phat_LicenseAgreementDescription
Namespace Prefix: | phat_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum amount payable in sales milestones upon the achievement of specified levels of product sales. + References No definition available. + Details
Name: | phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment for license amount. + References No definition available. + Details
Name: | phat_PaymentForLicenseAmount
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchase commitment, expense. + References No definition available. + Details
Name: | phat_PurchaseCommitmentExpense
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase obligation due in first twenty four months. + References No definition available. + Details
Name: | phat_PurchaseObligationDueInFirstTwentyFourMonths
Namespace Prefix: | phat_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Warrants expiration date. + References No definition available. + Details
Name: | phat_WarrantsExpirationDate
Namespace Prefix: | phat_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |